Vaccines

April 8, 2015

VU joins national effort to speed Ebola therapy testing

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

By Bill Snyder
January 29, 2015

Core facilities key driver of VUMC research gains

During the past five years, Vanderbilt University Medical Center has become a leader in “personalized medicine,” the use of genomic information to individualize patient care.

By Bill Snyder
November 13, 2014

Speaker explores promise of ‘bioelectronic medicine’

Can an implanted electrical device like a cardiac pacemaker effectively treat inflammatory diseases like rheumatoid arthritis, including cases that have not responded to drug therapy?

By Bill Snyder
September 18, 2014

Initiative seeks to develop therapies to combat Ebola

Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.

By Bill Snyder
April 7, 2014

Vanderbilt Vaccine Center joins global task force to address urgent viral threat

By John Howser
syringe
March 6, 2014

Multi-center effort targets lethal Ebola, Marburg viruses

Vanderbilt University researchers are collaborating in a multi-center, federally-funded project to develop ways to treat and prevent the highly lethal Ebola and Marburg virus infections.

By Bill Snyder
August 22, 2013

Vaccine researchers ready as new flu strain evolves

A worrisome new avian influenza virus, called H7N9, emerged this spring in Eastern China.
By VUMC News and Communications
May 30, 2013

Study lays groundwork for rational T cell vaccine design

Vanderbilt University investigators have developed a new strategy for identifying the “bits” of a pathogen that spark a protective immune response.
By Leigh MacMillan
May 16, 2013

Grant targets new therapies for Ebola, Marburg viruses

Vanderbilt’s James Crowe Jr., M.D., and a collaborator in Texas have been awarded a $4.4 million grant from the U.S. Department of Defense to study new ways to treat and prevent Ebola and Marburg viruses.
By VUMC News and Communications
July 19, 2012

Long antibodies better against HIV

Understanding how antibodies with long “loops” form may be important for HIV vaccine development.
By Leigh MacMillan
April 27, 2012

Dengue antibodies give vaccine leads

New information may help speed development of a vaccine or treatment for dengue fever.
By VUMC News and Communications
June 17, 2008

$2.4 million NIH grant puts Children’s Hospital researcher at forefront of new direction in HIV research

After recent efforts to develop a vaccine to protect against AIDS proved ineffective, the National Institutes of Health announced a change in research direction; and it\'s one that will involve the lab of James Crowe, M.D., professor of Pediatrics, Microbiology and Immunology at the Monroe Carell Jr. Children\'s Hospital at Vanderbilt.
By VUMC News and Communications
September 27, 2004

Vanderbilt University Medical Center Launches Genital Herpes Vaccine Trial

Vanderbilt University Medical Center researchers are launching a clinical trial of Herpavac, a new genital herpes vaccine that has proven effective in previous clinical trials in preventing the spread of the herpes simplex virus in women.
By VUMC News and Communications